Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Monday, September 14, 2026

Back to today

From X

@BrokenMoats 1 click

Broken Moats on X

$BSP lockup comes right at the end of the year....might want to file that date away, and go read the S1. Difficult to find a more flawed business model and aggregios valuation then this. It is Upland reincarnated and perhaps Valeant if they start getting dodgy on their receivables as financing starts drying up. BSP business is simply a game of removing almost all costs of broken, zombie software companies (bring r&d to near zero, remove a bulk of the employees, jack the price to any residual customers, report improved metrics, do not report the metrics you do not want to show (stopped reporting NRR, other metrics post IPO). An Italian based rollup of a collection of 2012 point solutions (Vimeo, Brightcove, Eventbrite, AOL (yes that AOL), and a bunch of others that were failed investments on their own right and in decline. Very little in shared synergies. The cadence of deals and size of deals has been dramatically increasing since 2003 (as you would expect). sub 300m in 2023, 800m in 2024, 2B in 2025, and already at 4B for 2026. This law of large numbers will continue to have to scale to continue to be able to show the financial wizardly of improved adjusted profits. Because as the cohorts exhaust the initial boost from price increases and cost cuts the businesses start more aggressively shedding their customer base (increasing the melt of the ice cube), so before these metrics infect their financials they need new deals to over run the melt (not a coincidence deal flow is faster and bigger). And thats the game, the equity price (and future dilution a certainty) (as they are around 6-7B net debt once they close their recent acquisition, this is post the ipo raise too). Once/if the story, law of numbers cannot run anymore to the right with financing, the gig will be up. Plenty of prior versions of this exact model as predecessors just go look at Upland software $UPLD. Won't end well but weird float dynamics with the A shares, IPO, lockup (12/28) and the aggressiveness of software/semi currently that is squeezing lots of more obvious AI disrupted software vendors, so its obvious where their ends up ultimately but might be treacherous on its path there, certainly tough until the float increases to short. Should be fun to watch, and an opportunity once liquidity opens up
@KEDM_COM 1 click

KEDM.com on X

Workiva $WK came through our monitor when Meditation Capital @timothyhliu5 ran a deep dive on it. The Fund has been buying application software at 2–3x sales after 105 expert calls, arguing infrastructure and cybersecurity have already repriced as AI winners while application names have not. It describes Workiva as the near-monopoly platform for SEC reporting: 95% of the Fortune 100, 89% of the S&P 500, an estimated ~50% of US filers and ~85% of filer market capitalization.

Investor Letters

All letters

Alarm.com: False Alarm?

Alarm.com, founded after CEO Steve Trundle’s bad home-security experience, has fallen from $105 in 2020 to about $55, testing whether…

ALRM $2.6B
TSOH Investment Research 1 click

Unpolished Thoughts on Stocks #1

Genius Sports aims to turn official sports data into AI-driven, real-time advertising, with media and ads already about 40% of revenue.

GENI $1.6B
Sylence Capital 2 clicks

Lululemon: The 15-Minute Thesis

Lululemon’s North American sales, margins and legging demand are falling as Alo and Vuori gain share, leaving its brand moat and depressed…

LULU $11B
Hated Moats 2 clicks
SLS · short

Sellas Life Sciences Group I

SELLAS Life Sciences Group faces a short case arguing that even a strong clinical outcome does not support its current valuation.

SLS $2.3B
Value Investors Club

ALTO- ALTO ingredients

ALTO Ingredients trades near half of book value after plant upgrades and lower corn prices set up a recovery in crush margins and cash flow.

ALTO $296M
Sylence Capital 1 click

Notes and Updates

ECIP recipient banks could repurchase Treasury preferred shares at steep discounts, potentially lifting book value, while Hawaiian Electric…

HE $1.7BUBAB $199M
Exploring with Alluvial Capital

Mereo Biopharma

Mereo Biopharma has two late-stage assets, seeks non-dilutive financing for alvelestat Phase 3 trials, and reports cash runway through 2027.

MREO $54M
Raging Bull Investments

JBG Smith

JBG Smith trades at an estimated 40% discount to NAV, backed by National Landing multifamily assets, Amazon HQ demand and $1.3 billion of…

JBGS $795M
Raging Bull Investments

Some Thoughts on Roaring Kitty

Roaring Kitty’s GameStop resurgence revisits GME shareholder activism and the meme-stock trading episode, with references to Bed Bath &…

GME $12B
Rod’s Ruminations

Publications we follow

Every publication on this site, hand-picked.

108 publications

Newsletters 91

YouTube 4

Blogs 12

Seeking Alpha 30 of 163

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

69 accounts
Nominate an account

Investor letters we follow

78 firms

Sectors

Ordered by how often our editor reaches for them.